What are the chances? Clinician scientist` career pathways in Germany.

Clinician scientist programs Clinician scientists Research training Translational medicine Translational training

Journal

BMC medical education
ISSN: 1472-6920
Titre abrégé: BMC Med Educ
Pays: England
ID NLM: 101088679

Informations de publication

Date de publication:
07 Sep 2023
Historique:
received: 28 03 2023
accepted: 11 08 2023
medline: 11 9 2023
pubmed: 8 9 2023
entrez: 7 9 2023
Statut: epublish

Résumé

Germany faces a lack of clinician scientists. This problem is widely acknowledged, not just in Germany, as clinician scientists are crucial for medical translation and innovation: trained in medical practice and research they are capable of translating scientific problems into clinical application and vice versa, clinical problems into research. The implementation of nationwide clinician scientist programs (CSPs) in Germany is supposed to solve the lack of trained clinician scientists and, as consequence, to improve the translational relationship between biomedical research and clinical practice. Against the backdrop of an increasing number of CSPs, our study provides early insights into their effectiveness with a focus on what it means to become a clinician scientist and to establish a subsequent career path as a clinician scientist in Germany. During a research project that was conducted from 2020 to 2023 and funded by the German Federal Ministry of Education and Research, we studied thirteen CSPs. We developed a qualitative questionnaire and interviewed 36 clinician scientists in training, their program supervisors, as well as policy stakeholders. The goal of the interviews was to identify the key obstacles in establishing a career path for clinician scientists in Germany. We found three types of challenges for establishing and ensuring long term career paths for clinician scientists: First, local working conditions need to allow for clinician scientists to create and perform tasks that combine research, teaching, patient care and translation synergistically. Protection from the urgency of patient care and from metrics-based performance measures both in the clinic and in research seem key here. Second, a stable career path requires new target positions besides clinic management and senior residency. Third, there is a need for cultural change within university medicine that recognizes and rewards new translation-focused practices. We find that CSPs improve working conditions for the duration of the program and provide protected time for doing research. After the programs, however, the career paths remain unstable, mainly due to a lack of target positions for clinician scientists. CSPs support the initial development of the clinician scientist' role, but not in a sustainable way, because the separation of research and patient care is stabilized on an institutional and systemic level. The tasks clinician scientists perform in research remain separate from patient care and teaching, thus, limiting their translational potential. In order to remain a clinician scientist within this differentiated system of university medicine, clinician scientists have to do a significant amount of extra work.

Sections du résumé

BACKGROUND BACKGROUND
Germany faces a lack of clinician scientists. This problem is widely acknowledged, not just in Germany, as clinician scientists are crucial for medical translation and innovation: trained in medical practice and research they are capable of translating scientific problems into clinical application and vice versa, clinical problems into research. The implementation of nationwide clinician scientist programs (CSPs) in Germany is supposed to solve the lack of trained clinician scientists and, as consequence, to improve the translational relationship between biomedical research and clinical practice. Against the backdrop of an increasing number of CSPs, our study provides early insights into their effectiveness with a focus on what it means to become a clinician scientist and to establish a subsequent career path as a clinician scientist in Germany.
METHODS METHODS
During a research project that was conducted from 2020 to 2023 and funded by the German Federal Ministry of Education and Research, we studied thirteen CSPs. We developed a qualitative questionnaire and interviewed 36 clinician scientists in training, their program supervisors, as well as policy stakeholders. The goal of the interviews was to identify the key obstacles in establishing a career path for clinician scientists in Germany.
RESULTS RESULTS
We found three types of challenges for establishing and ensuring long term career paths for clinician scientists: First, local working conditions need to allow for clinician scientists to create and perform tasks that combine research, teaching, patient care and translation synergistically. Protection from the urgency of patient care and from metrics-based performance measures both in the clinic and in research seem key here. Second, a stable career path requires new target positions besides clinic management and senior residency. Third, there is a need for cultural change within university medicine that recognizes and rewards new translation-focused practices.
CONCLUSION CONCLUSIONS
We find that CSPs improve working conditions for the duration of the program and provide protected time for doing research. After the programs, however, the career paths remain unstable, mainly due to a lack of target positions for clinician scientists. CSPs support the initial development of the clinician scientist' role, but not in a sustainable way, because the separation of research and patient care is stabilized on an institutional and systemic level. The tasks clinician scientists perform in research remain separate from patient care and teaching, thus, limiting their translational potential. In order to remain a clinician scientist within this differentiated system of university medicine, clinician scientists have to do a significant amount of extra work.

Identifiants

pubmed: 37679714
doi: 10.1186/s12909-023-04584-8
pii: 10.1186/s12909-023-04584-8
pmc: PMC10486072
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

642

Subventions

Organisme : Bundesministerium für Bildung und Forschung
ID : EA4/093/22

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

Elife. 2022 Sep 13;11:
pubmed: 36098684
Clin Invest Med. 2011 Dec 01;34(6):E324
pubmed: 22129920
Acad Med. 2022 Sep 1;97(9):1277-1280
pubmed: 35731582
EMBO Mol Med. 2022 Feb 7;14(2):e14334
pubmed: 34927359
Healthc Q. 2019 Apr;22(1):60-66
pubmed: 31244470
Aust Health Rev. 2021 Jun;45(3):308-310
pubmed: 33287948
BMC Med Educ. 2017 Dec 08;17(1):242
pubmed: 29216896
BMJ Open. 2018 Mar 3;8(3):e020398
pubmed: 29502093
Clin Invest Med. 2020 Dec 27;43(4):E2-7
pubmed: 33370519
J Clin Invest. 2015 Nov 03;125(12):4317-9
pubmed: 26529253

Auteurs

Barbara Hendriks (B)

Robert K. Merton Center for Science Studies (RMZ) at Humboldt-Universität zu Berlin, Berlin, Germany. barbara.hendriks@hu-berlin.de.

Martin Reinhart (M)

Robert K. Merton Center for Science Studies (RMZ) at Humboldt-Universität zu Berlin, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH